{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/REPL/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-19T19:08:23.303Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":4308,"canonical_name":"Replimune Group, Inc.","cik":"0001737953","uei":null,"lei":null,"duns":null,"ticker":"REPL"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":46,"clinical":1},"count":47,"timeline":[{"ts":"2026-09-16","kind":"sec.filing","form_type":"8-K","title":"8-K — Replimune Group, Inc. — 2026-09-16","url_slug":"/sec/cik-0001737953/8-k/0001104659-26-108243","accession_number":"0001104659-26-108243","importance":35},{"ts":"2026-08-19","kind":"sec.filing","form_type":"4","title":"4 — Replimune Group, Inc. — 2026-08-19","url_slug":"/sec/cik-0001737953/4/0001104659-26-098868","accession_number":"0001104659-26-098868","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Replimune Group, Inc. — 2026-08-14","url_slug":"/sec/cik-0001737953/10-q/0001628280-26-057099","accession_number":"0001628280-26-057099","importance":45},{"ts":"2026-08-14","kind":"sec.filing","form_type":"8-K","title":"8-K — Replimune Group, Inc. — 2026-08-14","url_slug":"/sec/cik-0001737953/8-k/0001104659-26-096483","accession_number":"0001104659-26-096483","importance":35},{"ts":"2026-08-14","kind":"sec.filing","form_type":"S-3ASR","title":"S-3ASR — Replimune Group, Inc. — 2026-08-14","url_slug":"/sec/cik-0001737953/s-3asr/0001104659-26-097309","accession_number":"0001104659-26-097309","importance":30},{"ts":"2026-08-12","kind":"sec.filing","form_type":"4","title":"4 — Replimune Group, Inc. — 2026-08-12","url_slug":"/sec/cik-0001737953/4/0001104659-26-095003","accession_number":"0001104659-26-095003","importance":30},{"ts":"2026-08-12","kind":"sec.filing","form_type":"4","title":"4 — Replimune Group, Inc. — 2026-08-12","url_slug":"/sec/cik-0001737953/4/0001104659-26-095006","accession_number":"0001104659-26-095006","importance":30},{"ts":"2026-08-12","kind":"sec.filing","form_type":"4","title":"4 — Replimune Group, Inc. — 2026-08-12","url_slug":"/sec/cik-0001737953/4/0001104659-26-095008","accession_number":"0001104659-26-095008","importance":30},{"ts":"2026-08-12","kind":"sec.filing","form_type":"4","title":"4 — Replimune Group, Inc. — 2026-08-12","url_slug":"/sec/cik-0001737953/4/0001104659-26-095012","accession_number":"0001104659-26-095012","importance":30},{"ts":"2026-08-11","kind":"sec.filing","form_type":"8-K/A","title":"8-K/A — Replimune Group, Inc. — 2026-08-11","url_slug":"/sec/cik-0001737953/8-k-a/0001104659-26-093512","accession_number":"0001104659-26-093512","importance":30},{"ts":"2026-08-10","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Replimune Group, Inc. — 2026-08-10","url_slug":"/sec/cik-0001737953/schedule-13g/0000886982-26-000320","accession_number":"0000886982-26-000320","importance":55},{"ts":"2026-08-10","kind":"sec.insider.s","reporter":"Patel Sushil","title":"Chief Executive Officer","shares":39341,"price_per_share":12.97,"usd_value":510253,"security_title":"Common Stock","importance":35.51025277},{"ts":"2026-08-10","kind":"sec.insider.s","reporter":"Hill Emily Luisa","title":"Chief Financial Officer","shares":11448,"price_per_share":12.97,"usd_value":148481,"security_title":"Common Stock","importance":35.14848056},{"ts":"2026-08-10","kind":"sec.insider.s","reporter":"Xynos Konstantinos","title":"Chief Medical Officer","shares":11447,"price_per_share":12.97,"usd_value":148468,"security_title":"Common Stock","importance":35.14846759},{"ts":"2026-08-10","kind":"sec.insider.s","reporter":"Schwendenman Andrew","title":"Chief Accounting Officer","shares":7632,"price_per_share":12.97,"usd_value":98987,"security_title":"Common Stock","importance":35.09898704},{"ts":"2026-08-10","kind":"sec.filing","form_type":"8-K","title":"8-K — Replimune Group, Inc. — 2026-08-10","url_slug":"/sec/cik-0001737953/8-k/0001104659-26-093042","accession_number":"0001104659-26-093042","importance":35},{"ts":"2026-08-10","kind":"sec.filing","form_type":"424B5","title":"424B5 — Replimune Group, Inc. — 2026-08-10","url_slug":"/sec/cik-0001737953/424b5/0001104659-26-093040","accession_number":"0001104659-26-093040","importance":30},{"ts":"2026-08-07","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Replimune Group, Inc. — 2026-08-07","url_slug":"/sec/cik-0001737953/schedule-13g/0000093751-26-000533","accession_number":"0000093751-26-000533","importance":55},{"ts":"2026-08-07","kind":"sec.filing","form_type":"8-K","title":"8-K — Replimune Group, Inc. — 2026-08-07","url_slug":"/sec/cik-0001737953/8-k/0001104659-26-092246","accession_number":"0001104659-26-092246","importance":35},{"ts":"2026-07-31","kind":"sec.filing","form_type":"8-K","title":"8-K — Replimune Group, Inc. — 2026-07-31","url_slug":"/sec/cik-0001737953/8-k/0001104659-26-088857","accession_number":"0001104659-26-088857","importance":35},{"ts":"2026-07-30","kind":"sec.filing","form_type":"8-K","title":"8-K — Replimune Group, Inc. — 2026-07-30","url_slug":"/sec/cik-0001737953/8-k/0001104659-26-088481","accession_number":"0001104659-26-088481","importance":35},{"ts":"2026-07-29","kind":"sec.filing","form_type":"DEF 14A","title":"DEF 14A — Replimune Group, Inc. — 2026-07-29","url_slug":"/sec/cik-0001737953/def-14a/0001104659-26-087650","accession_number":"0001104659-26-087650","importance":40},{"ts":"2026-07-29","kind":"sec.filing","form_type":"ARS","title":"ARS — Replimune Group, Inc. — 2026-07-29","url_slug":"/sec/cik-0001737953/ars/0001104659-26-087654","accession_number":"0001104659-26-087654","importance":30},{"ts":"2026-07-29","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — Replimune Group, Inc. — 2026-07-29","url_slug":"/sec/cik-0001737953/defa14a/0001104659-26-087651","accession_number":"0001104659-26-087651","importance":30},{"ts":"2026-07-29","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — Replimune Group, Inc. — 2026-07-29","url_slug":"/sec/cik-0001737953/effect/9999999995-26-002486","accession_number":"9999999995-26-002486","importance":30},{"ts":"2026-07-24","kind":"sec.filing","form_type":"S-3/A","title":"S-3/A — Replimune Group, Inc. — 2026-07-24","url_slug":"/sec/cik-0001737953/s-3-a/0001104659-26-086680","accession_number":"0001104659-26-086680","importance":30},{"ts":"2026-07-13","kind":"sec.filing","form_type":"PRE 14A","title":"PRE 14A — Replimune Group, Inc. — 2026-07-13","url_slug":"/sec/cik-0001737953/pre-14a/0001104659-26-083158","accession_number":"0001104659-26-083158","importance":30},{"ts":"2026-06-29","kind":"sec.filing","form_type":"10-K","title":"10-K — Replimune Group, Inc. — 2026-06-29","url_slug":"/sec/cik-0001737953/10-k/0001628280-26-045886","accession_number":"0001628280-26-045886","importance":55},{"ts":"2026-06-29","kind":"sec.filing","form_type":"8-K","title":"8-K — Replimune Group, Inc. — 2026-06-29","url_slug":"/sec/cik-0001737953/8-k/0001104659-26-078511","accession_number":"0001104659-26-078511","importance":35},{"ts":"2026-06-29","kind":"sec.filing","form_type":"S-8","title":"S-8 — Replimune Group, Inc. — 2026-06-29","url_slug":"/sec/cik-0001737953/s-8/0001104659-26-078583","accession_number":"0001104659-26-078583","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"8-K","title":"8-K — Replimune Group, Inc. — 2026-06-26","url_slug":"/sec/cik-0001737953/8-k/0001104659-26-078009","accession_number":"0001104659-26-078009","importance":35},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — Replimune Group, Inc. — 2026-06-03","url_slug":"/sec/cik-0001737953/4/0001104659-26-070256","accession_number":"0001104659-26-070256","importance":30},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Sarchi Christopher","title":"Chief Commercial Officer","shares":12000,"price_per_share":9.24,"usd_value":110880,"security_title":"Common Stock","importance":35.11088},{"ts":"2026-05-21","kind":"sec.13dg","reporter":"Ridgeback Capital Investments L.P.","shares":6252651,"percent_of_class":7.6,"security_title":"SCHEDULE 13G","accession_number":"0001104659-26-065261","excerpt":null,"importance":55},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Replimune Group, Inc. — 2026-05-20","url_slug":"/sec/cik-0001737953/4/0001104659-26-064517","accession_number":"0001104659-26-064517","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Replimune Group, Inc. — 2026-05-20","url_slug":"/sec/cik-0001737953/4/0001104659-26-064519","accession_number":"0001104659-26-064519","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Replimune Group, Inc. — 2026-05-20","url_slug":"/sec/cik-0001737953/4/0001104659-26-064523","accession_number":"0001104659-26-064523","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Replimune Group, Inc. — 2026-05-20","url_slug":"/sec/cik-0001737953/4/0001104659-26-064525","accession_number":"0001104659-26-064525","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Replimune Group, Inc. — 2026-05-20","url_slug":"/sec/cik-0001737953/4/0001104659-26-064526","accession_number":"0001104659-26-064526","importance":30},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Patel Sushil","title":"Chief Executive Officer","shares":37324,"price_per_share":5.08,"usd_value":189606,"security_title":"Common Stock","importance":35.18960592},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Astley-Sparke Philip","title":"","shares":17657,"price_per_share":5.08,"usd_value":89698,"security_title":"Common Stock","importance":35.08969756},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Xynos Konstantinos","title":"Chief Medical Officer","shares":14023,"price_per_share":5.08,"usd_value":71237,"security_title":"Common Stock","importance":35.07123684},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Sarchi Christopher","title":"Chief Commercial Officer","shares":8626,"price_per_share":5.08,"usd_value":43820,"security_title":"Common Stock","importance":35.04382008},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Schwendenman Andrew","title":"Chief Accounting Officer","shares":7894,"price_per_share":5.08,"usd_value":40102,"security_title":"Common Stock","importance":35.04010152},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Hill Emily Luisa","title":"Chief Financial Officer","shares":7812,"price_per_share":5.08,"usd_value":39685,"security_title":"Common Stock","importance":35.03968496},{"ts":"2026-05-12","kind":"sec.13dg","reporter":"SUVRETTA CAPITAL MANAGEMENT, LLC","shares":4221836,"percent_of_class":5.1,"security_title":"SCHEDULE 13G","accession_number":"0000919574-26-002901","excerpt":null,"importance":55},{"ts":"2026-04-22","kind":"clinical.trial","reporter":"Replimune, Inc.","title":"Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies","security_title":"PHASE1,PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04349436","excerpt":"[\"Merkel Cell Carcinoma\",\"Basal Cell Carcinoma\",\"Locally Advanced Cutaneous Squamous Cell Carcinoma\",\"Cancer\"]","importance":45}]}